KORU Medical Systems Third Quarter 2026 Earnings Call - KORU MEDICAL SYSTEMS INC

Financial Performance:

• Q3 2026 revenue reached $11.6 million, reflecting 11% year-over-year (YoY) growth.
• Gross margins expanded 500 basis points to 65.2% (vs. 60.2% in the prior year), driven by lower manufacturing costs, favorable geographic mix, and supply chain efficiencies.
• The company achieved its second consecutive quarter of positive net income ($200,000) and positive adjusted EBITDA ($2.2 million for the quarter, representing an 18x YoY improvement).
• Year-to-date (YTD) revenue was $35.4 million (17% growth), with gross margins at 64% and operating expenses as a percentage of sales improving to 64%.
• Net loss narrowed significantly to $300,000 YTD (an 84% improvement YoY), with the business operating near break-even.
• Cash position ended at $7.4 million with an undrawn $10 million credit facility; cash usage was $900,000 for the quarter, primarily driven by working capital inventory build for Q4.
• Domestic core revenue grew 32% reported (10% normalized after adjusting for one-time $1.2M distributor impacts in the prior year).
• International revenue declined 17% reported but grew 23% normalized, driven by new patient starts.
• Pharma services and clinical trials revenue declined 27% YoY due to lower clinical trial ordering variability.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance raised to $48.0–$48.5 million (17–18% growth).
• Full-year gross margin guidance raised to 63–64%.
• Full-year adjusted EBITDA is expected to be positive; year-end cash balance target raised to >$8 million.
• Q4 2026 is expected to deliver "high teens" growth, with core revenue accounting for the bulk of the acceleration.
• Long-term strategic targets remain unchanged: $100 million in revenue, gross margins >65%, and EBITDA margins ≥20%.
• Q2 2027 is projected to generate positive cash flow of at least $600,000.

Business Segments and Product Lines:

• Core IG Business: Remains the global leader in large-volume subcutaneous drug delivery; supports ~60,000 recurring chronic immunoglobulin patients.
• Restivio (Home Care): Three U.S. specialty pharmacies now dispensing the drug via Co-Root systems; potential for ~100,000 infusions over 3–5 years.
• International Expansion: Signed new distribution agreements in a major European market (integrating wholesaler, home care, and pharmacy) and a new partner in Africa; initial orders shipped and expected to drive Q4 revenue.
• New Product Development: Regulatory submission for "Freedom360" (next-gen pump) on track for year-end approval, targeting high-volume patients; connected monitoring technology prototypes are in functional testing with enthusiastic pharma feedback.
• Pipeline Advancements:
  • Takeda SCIG: Pivotal trial data shows 50% volume reduction and 40% shorter infusion times vs. competitor Hycuvia.
  • Enzyme Replacement Therapy: Phase 3 trial underway for ~5,000 patient population.
  • Nephrology: Phase 3 trial execution supported for ~10,000 patient population.
  • Deferoxamine: 510K application under FDA review for label expansion; anticipated contribution in 2027.
  • Oncology: Strong focus on high-value strategic assets; commercial details expected in H1 2027.
  • Secondary Immunodeficiency: Pivotal trial endpoints expected late 2026.

Market and Competitive Landscape:

• The global SCIG market is growing at 8–10% annually (quarterly growth of 1.8–2%).
• KORU is projected to hold approximately 20% market share in international markets, with opportunities to expand in non-tender (distributor-based) and tender (pharma-led) models.
• Competition exists in tender markets where device selection is tied to pharmaceutical tenders, and in non-tender markets where growth is account-by-account.
• KORU maintains a competitive moat through its recurring patient base and ability to support the industry shift toward home-based, patient-administered therapies.
• New partnerships in Europe leverage integrated networks (wholesaler + home care + pharmacy) to streamline market access.

Risks and Challenges:

• International Execution: Slower growth in Q3 attributed to navigating competitive distributor-based markets and tender processes; ramp-up in new geographies (Africa/Europe) may vary.
• Pharmaceutical Partnerships: Drug label expansions depend on external pharma development timelines, regulatory approvals (FDA), and partner disclosures; specific oncology and partnership details are proprietary.
• Variable Revenue: Pharma services and clinical trial revenue remains unpredictable and lumpy based on client drug program timing.
• Regulatory Timelines: FDA approval timelines for new indications (e.g., Deferoxamine) and new devices (Freedom360) are subject to agency review periods (90–180 days for 510K).
• Supply Chain/Tariffs: While lower tariffs aided margins, reliance on a single CMO contract requires ongoing volume/pricing negotiations.

Management Commentary and Tone:

• Tone: Confident, disciplined, and optimistic; management emphasized "proof points" and "momentum" over immediate inflection dates.
• Strategy: Focus on executing the core profitable business while strategically investing in new geographies, drug labels, and connected health technology.
• Confidence: CEO Adam Calbermatten expressed strong belief in the "inflection" point for the business, citing the robust recurring revenue base that funds future growth.
• Transparency: Management openly addressed Q3 slowdown as temporary (trough) and attributed it to distributor timing rather than fundamental weakness.

Analyst Questions and Answers:

• 2027 International Cadence: Management expects new distribution agreements to start delivering orders in Q4 and continuing growth into 2027, though specific 2027 budgeted figures are not yet set.
• SCIG Market Health: Confirmed domestic and international SCIG market growth of 8–10% YoY with consistent quarterly performance.
• 2027 Strategy Confidence: High confidence in U.S. core growth (10–15%), Restivio/Specialty Pharmacy channel, Deferoxamine clearance, and Freedom360 launch in 2027.
• Q4 Revenue Split: Core revenue expected to drive the full year, with Q4 growth anticipated to be in the high teens.
• New Geographies: Active expansion into Europe and Africa via both tender and non-tender models; future expansion anticipated in 2027.
• Market Share: Approx. 20% international share with upside potential through cost-saving solutions and convenience for self-administration.
• Freedom360 Impact: Targeted at high-volume patients requiring multiple syringes to improve experience; launch timeline hinges on 510K approval followed by specialty pharmacy evaluations.

Other Key Points:

• The Q3 results marked a structural improvement with back-to-back quarters of profitability, validating the unit economics and operational leverage.
• Normalized growth metrics (Domestic +10%, International +23%) highlight strong underlying performance distinct from one-time Q3 2025 distributor anomalies.
• The "Connected Health" asset acquisition is yielding functional prototypes with positive early feedback from pharma partners regarding real-time data insights.
• Management confirmed that the one-time $1M technology acquisition expense in Q2 is the primary reason for higher YTD cash usage, though underlying cash consumption has improved.